Ackermans & van Haaren NV

Ackermans & van Haaren Trading Update 3Q2025: Excellent results of core participations, FY2025 Outlook confirmed

21 Nov 2025 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren invests 22 million euros in VKC Nuts

25 Sep 2025 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros

04 Sep 2025 01:15:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren commits 20 million US dollars to the second fund of Venturi Partners

02 Sep 2025 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren: First-Half 2025 Results

29 Aug 2025 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren: the General Shareholders' Meeting approves all proposed resolutions by a vast majority

26 May 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren (Trading Update Q1 2025): AvH reports solid start to the year and confirms guidance

22 May 2025 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren: publication of a transparency notification

04 Apr 2025 11:42:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren grows net profit by 15% in 2024 to 460 million euros.

28 Feb 2025 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren Trading Update Q3 2024 - AvH is on track towards a net profit well above 400 million euros

22 Nov 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren and the Delen family confirm their long-term partnership with updated shareholder arrangements in respect of Delen Private Bank and Bank J. Van Breda & Co

21 Nov 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren invests an additional 5 million euros in Biotalys

14 Oct 2024 02:15:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren: Outstanding results in core participations result in a strong increase of AvH's net profit for 1H2024 to EUR 200 million (+17%)

30 Aug 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company

26 Jul 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haare invests in V.Group, a leading provider of marine support services

17 Jun 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren: the General Shareholders' Meeting approves all proposed resolutions by a large majority

27 May 2024 12:35:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren reports outstanding Q1-results at both DEME and at the private banks Delen and Van Breda, and gives confirmation of guidance: net profit of 2024 expected to be higher than last year

23 May 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren realised a net profit of 399.2 million euros, thanks to a record performance of its core participations

29 Feb 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren: Well on track to post a solid set of results for the full year 2023

23 Nov 2023 01:00:00 بحسب Nasdaq GlobeNewswire

Ackermans & van Haaren realised a net profit of 170.7 million euros over the first half of 2023 and is well on track to deliver another strong set of results for the whole year of 2023

31 Aug 2023 01:00:00 بحسب Nasdaq GlobeNewswire